- Two abstracts win the prestigious AHA 2024 Paul Dudley White International Scholar Award
Allschwil, Switzerland – September 5, 2024
Idorsia Ltd (SIX: IDIA) today announced that new data on aprocitentan, Idorsia’s endothelin receptor antagonist, will be presented at the American Heart Association (AHA) Hypertension Scientific Sessions 2024, taking place in Chicago, Illinois, September 5–8, 2024. On March 19, 2024, aprocitentan was approved as TRYVIO™ in the US, with availability planned for Q4 2024. On June 27, 2024, the European Commission granted market authorization for JERAYGO™ (aprocitentan).
The following oral and poster presentations will be held:
- Blattmann P, et al. “Correlation between plasma CT-proET-1 and renal dysfunction in patients with resistant hypertension. A biomarker analysis of the PRECISION study.”, poster presentation by Martine Clozel, Poster session 2, salon D, Sep 6, 9am – 10.30am.
- Clozel M, et al. "Is aprocitentan also sympatholytic in patients with resistant hypertension?”, poster presentation by Martine Clozel, Poster session 2, salon D, Sep 6, 9am – 10.30am.
- Schlaich M, et al. “Impact of arterial stiffness on the blood pressure lowering effect of the dual endothelin antagonist aprocitentan in patients with resistant hypertension”, poster presentation by Markus Schlaich, Poster session 2, salon D, Sep 6, 9am – 10.30am.
- Weber M, et al. “Efficacy and safety of aprocitentan in patients with resistant hypertension and elevated NT-proBNP”, moderated poster presentation by Michael Weber, Session MPS02, Salon D, New Paradigm and lessons learnt from Hypertension Clinical Trials in 2024, Sep 6, 9.15am – 9.20am.
- Iglarz M, et al. “Effect of the endothelin receptor antagonist aprocitentan on plasma endothelin, renin and aldosterone concentrations in patients with resistant hypertension. A biomarker analysis of the PRECISION study.”, oral presentation by Martine Clozel, Session 12.A, Anti-hypertensive drugs, Sep 6, 5:30pm – 5:45pm. Winner of the prestigious AHA 2024 Paul Dudley White International Scholar Award.
- Schlaich M, et al. “A major effect of aprocitentan on albuminuria in patients with resistant hypertension”, oral presentation by Markus Schlaich, Session 14.A, Novel interventions in improving BP control in the digital era, Sep 7, 8.45am – 9am. Winner of the prestigious AHA 2024 Paul Dudley White International Scholar Award.
More information can be found on the congress website.
Notes to the editor
About the AHA 2024 Paul Dudley White International Scholar Award
The award is presented to the primary author of the highest ranked abstract submitted from each country to the American Heart Association’s Hypertension Scientific Sessions 2024. This award is named for Dr. Paul Dudley White, who was a founding father of the American Heart Association and an early leader in preventive cardiology. It reflects Dr. White’s vision for global excellence in cardiovascular science and medicine.
About aprocitentan
Aprocitentan is Idorsia’s once-daily, orally active, dual endothelin receptor antagonist, which inhibits the binding of ET-1 to ETA and ETB receptors. In May 2022, Idorsia announced positive top-line results of the Phase 3 PRECISION study with aprocitentan for the treatment of patients with resistant hypertension. Detailed results were published in The Lancet and presented as a Late-Breaking Science presentation during the American Heart Association (AHA) Scientific Sessions in November 2022. More details and commentary can be found in the dedicated press release and an investor webcast featuring Prof. Markus Schlaich, an investigator in PRECISION. On March 19, 2024, aprocitentan was approved as TRYVIO™ in the US, with availability planned for Q4 2024. On June 27, 2024, the European Commission granted market authorization for JERAYGO™ (aprocitentan).
About Idorsia
Idorsia Ltd is reaching out for more – We have more ideas, we see more opportunities and we want to help more patients. In order to achieve this, we will develop Idorsia into a leading biopharmaceutical company, with a strong scientific core.
Headquartered near Basel, Switzerland – a European biotech-hub – Idorsia is specialized in the discovery, development and commercialization of small molecules to transform the horizon of therapeutic options. Idorsia has a 25-year heritage of drug discovery, a broad portfolio of innovative drugs in the pipeline, an experienced team of professionals covering all disciplines from bench to bedside, and commercial operations in Europe and North America – the ideal constellation for bringing innovative medicines to patients.
Idorsia was listed on the SIX Swiss Exchange (ticker symbol: IDIA) in June 2017 and has over 750 highly qualified specialists dedicated to realizing our ambitious targets.
For further information, please contact
Andrew C. Weiss
Senior Vice President, Head of Investor Relations & Corporate Communications
Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, CH-4123 Allschwil
+41 58 844 10 10
investor.relations@idorsia.com
media.relations@idorsia.com
www.idorsia.com
The above information contains certain "forward-looking statements", relating to the company's business, which can be identified by the use of forward-looking terminology such as "estimates", "believes", "expects", "may", "are expected to", "will", "will continue", "should", "would be", "seeks", "pending" or "anticipates" or similar expressions, or by discussions of strategy, plans or intentions. Such statements include descriptions of the company's investment and research and development programs and anticipated expenditures in connection therewith, descriptions of new products expected to be introduced by the company and anticipated customer demand for such products and products in the company's existing portfolio. Such statements reflect the current views of the company with respect to future events and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements of the company to be materially different from any future results, performances or achievements that may be expressed or implied by such forward-looking statements. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected.
Attachment
